Linaclotide (Constella®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32014000449
English
Authors' recommendations: Linaclotide (Constella®) is recommended as an option for restricted use within NHS Wales. Linaclotide (Constella®) should be restricted for use in the following subpopulation within its licensed indication for the symptomatic treatment of moderate to severe irritable bowel syndrome (IBS) with constipation in adults: • Patients who have not responded adequately to or cannot tolerate antispasmodics and/or laxatives. Linaclotide (Constella®) is not recommended for use within NHS Wales outside of this subpopulation.
Details
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Irritable Bowel Syndrome
  • Peptides
  • Constipation
  • Guanylyl Cyclase C Agonists
Contact
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.